Cerevel Therapeutics Holdings, Inc.
DelistedCIK 1805387fmd_12G3R2BA31Q5ZDBCWCP16ZTHSFManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Mar 31, 2024, 18 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Total revenues | – | 0 | 0 | 0 | 0 |
| Research and development | 50 | 103 | 162 | 280 | 335 |
| Total operating expenses | 83 | 149 | 220 | 368 | 447 |
| Operating income | (83) | (149) | (220) | (368) | (447) |
| Interest expense | – | – | – | 4 | 11 |
| Interest and investment income | – | – | 0 | 14 | 44 |
| Other non-operating income (expense) | (46) | (3) | (5) | 7 | (18) |
| Income before taxes | (128) | (152) | (225) | (351) | (432) |
| Income tax expense | 0 | (0) | – | 0 | 1 |
| Net income from continuing operations | (128) | (152) | – | (352) | (433) |
| Net income | (128) | (152) | (225) | (352) | (433) |
| Net income to common shareholders | (128) | (148) | (225) | (352) | – |